Led by the moderator, the panelists discussed the rationale for targeting the KIT D816V mutation with tyrosine kinase inhibitors and reviewed six-month and three-year PIONEER trial data showing sustained reductions in symptom burden and improved quality of life with avapritinib in indolent systemic mastocytosis, with minimal treatment discontinuation due to adverse events.
The panelists examined how treatment goals differ between indolent and advanced systemic mastocytosis (SM) — the former focused on symptom control and quality of life, the latter also targeting disease modification to reduce mast cell burden and organ damage — and outlined the pharmacist's role in acute anaphylaxis management, including patient education on epinephrine use and antihistamine dosing.
Led by the moderator, the expert pharmacists examined the broad differential diagnosis for systemic mastocytosis (SM), including non-clonal mast cell activation syndrome, neuroendocrine tumors, myeloid neoplasms, and cutaneous mastocytosis, alongside the evolving landscape of KIT D816V mutation testing — from allele-specific PCR and digital droplet PCR to next-generation and Sanger sequencing — each with distinct sensitivity trade-offs.
Led by the moderator, the panelists discussed long-term complications such as osteoporosis, organ involvement, and recurrent anaphylaxis, along with common triggers including NSAIDs, opioids, alcohol, and physical exertion, highlighting symptom journaling as a practical tool for patient education.
Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.
Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.
Drs Anthony Perissinotti and Kirollos Hanna provide some important considerations for pharmacists in treating chronic lymphocytic leukemia.
Experts discuss the potential future use of CAR T-cell therapy and bispecific therapeutics for chronic lymphocytic leukemia based on data presented at ASH 2021.
Dr Anthony Perissinotti details an effective new therapy on the horizon in chronic lymphocytic leukemia.
Anthony Perissinotti and Kirollos Hanna discuss considerations for selecting treatment regimens in chronic lymphocytic leukemia.
Chronic lymphocytic leukemia experts debate how to prevent or reduce the risk of tumor lysis in patients.
Anthony Perissinotti, PharmD, BCOP, explains potential scenarios requiring anti-CD20 monoclonal antibodies as a therapy for chronic lymphocytic leukemia.
Key opinion leaders discuss data from the MURANO trial on a fixed-duration therapy for relapsed/refractory chronic lymphocytic leukemia.
A hematology expert describes data from clinical trials on venetoclax-based therapies for chronic lymphocytic leukemia.
Dr Anthony Perissinotti explains the new formulation of acalabrutinib for chronic lymphocytic leukemia presented at ASH 2021.
Kirollos Hanna, PharmD, BCPS, BCOP, discusses clinical trial data for second-generation BTK inhibitors for chronic lymphocytic leukemia.
Anthony Perissinotti, PharmD, BCOP, provides an overview of the available treatment options in chronic lymphocytic leukemia, highlighting the role of first-generation BTK inhibitors.
February 22nd 2022
February 8th 2022
January 25th 2022
